GLP-1 Agonist Therapy for Type 2 Diabetes Management

Primary Indications for GLP-1 Receptor Agonists

The American Diabetes Association recommends GLP-1 receptor agonists as first-line therapy for patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk factors, regardless of baseline HbA1c levels, due to their proven benefits in reducing major adverse cardiovascular events (MACE) 1, 2
GLP-1 receptor agonists are recommended for patients without established cardiovascular disease but with high-risk indicators, including age ≥55 years with coronary, carotid, or lower extremity artery stenosis >50%, left ventricular hypertrophy, eGFR <60 mL/min/1.73m², or albuminuria 1, 2, 3

The American Diabetes Association recommends GLP-1 receptor agonists for patients with type 2 diabetes and eGFR <60 mL/min/1.73m² or albuminuria ≥30 mg/g, particularly if SGLT2 inhibitors are not tolerated 3
GLP-1 receptor agonists can be used in patients with eGFR as low as 2 mL/min/1.73m² or UACR ≥30 mg/g with no dosage adjustments required 3

The American Diabetes Association prefers GLP-1 receptor agonists as add-on therapy when metformin alone is insufficient for glycemic control 4
GLP-1 receptor agonists are preferred over insulin when additional glucose-lowering therapy is needed beyond oral agents 4
GLP-1 receptor agonists are particularly beneficial in patients with obesity due to weight reduction effects 5

Patients with poorly controlled type 2 diabetes and obesity may benefit from GLP-1 receptor agonist therapy 3
Patients with high cardiovascular risk but without established disease may benefit from GLP-1 receptor agonist therapy 1, 2

Dulaglutide has shown cardiovascular benefits in the REWIND trial, including in patients without established cardiovascular disease 1, 2

The decision to treat with a GLP-1 receptor agonist to reduce MACE, heart failure hospitalization, CV death, or CKD progression should be considered independently of baseline HbA1c 1, 2

Metformin remains the preferred initial pharmacologic agent for most patients with type 2 diabetes, according to the American Diabetes Association 6
For patients with established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure, GLP-1 receptor agonists should be considered as part of the initial treatment regimen independent of HbA1c level, as recommended by the American College of Physicians and the American Diabetes Association 7, 6
When metformin alone is insufficient for glycemic control, GLP-1 receptor agonists are preferred as add-on therapy, as stated by the American Diabetes Association 6
In patients with type 2 diabetes who need greater glucose lowering than can be obtained with oral agents, GLP-1 receptor agonists are preferred to insulin when possible, according to the American Diabetes Association 6
For patients with CKD and eGFR ≥30 mL/min/1.73 m², treatment should include metformin and an SGLT2 inhibitor, with GLP-1 receptor agonists recommended if glycemic targets are not achieved, as recommended by the American College of Physicians 7

For youth with type 2 diabetes and obesity, GLP-1 receptor agonists have shown safety and efficacy for decreasing A1C and promoting weight loss, according to the American Diabetes Association 8

Consider patient preferences, comorbidities, eGFR, and costs when selecting specific GLP-1 receptor agonists, as recommended by the American College of Physicians and the American Diabetes Association 7, 9